Perspective Therapeutics IncNYSE American:CATX
- LAST PRICE4.3500
- TODAY'S CHANGE (%)0.2300 (5.5825%)
- Bid / Lots4.3200/ 1
- Ask / Lots4.3600/ 2
- Open / Previous Close4.1500 / 4.1200
- Day Range
- 52 Week Range
- Volume1,396,665
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CATX |
|---|---|---|
| 09:32 ET | 15308 | 4.198 |
| 09:33 ET | 1440 | 4.1714 |
| 09:35 ET | 14533 | 4.16 |
| 09:37 ET | 3375 | 4.2176 |
| 09:39 ET | 3505 | 4.22 |
| 09:42 ET | 6190 | 4.21 |
| 09:44 ET | 6548 | 4.235 |
| 09:46 ET | 9616 | 4.2885 |
| 09:48 ET | 8173 | 4.25 |
| 09:50 ET | 9300 | 4.295 |
| 09:51 ET | 2995 | 4.36 |
| 09:53 ET | 5934 | 4.33 |
| 09:55 ET | 6902 | 4.36 |
| 09:57 ET | 10571 | 4.36 |
| 10:00 ET | 9385 | 4.41 |
| 10:02 ET | 9370 | 4.4399 |
| 10:04 ET | 14120 | 4.38 |
| 10:06 ET | 4844 | 4.41 |
| 10:08 ET | 14657 | 4.39 |
| 10:09 ET | 4755 | 4.44 |
| 10:11 ET | 15487 | 4.4388 |
| 10:13 ET | 27202 | 4.435 |
| 10:15 ET | 17009 | 4.46 |
| 10:18 ET | 20153 | 4.465 |
| 10:20 ET | 11683 | 4.47 |
| 10:22 ET | 10861 | 4.4784 |
| 10:24 ET | 5957 | 4.435 |
| 10:26 ET | 16796 | 4.43 |
| 10:27 ET | 3678 | 4.435 |
| 10:29 ET | 14667 | 4.42 |
| 10:31 ET | 21213 | 4.39 |
| 10:33 ET | 8726 | 4.41 |
| 10:36 ET | 4450 | 4.42 |
| 10:38 ET | 37039 | 4.33 |
| 10:40 ET | 10573 | 4.345 |
| 10:42 ET | 12741 | 4.4 |
| 10:44 ET | 15661 | 4.37 |
| 10:45 ET | 2865 | 4.3788 |
| 10:47 ET | 35169 | 4.355 |
| 10:49 ET | 6739 | 4.36 |
| 10:51 ET | 48613 | 4.37 |
| 10:54 ET | 9429 | 4.375 |
| 10:56 ET | 9117 | 4.375 |
| 10:58 ET | 3907 | 4.38 |
| 11:00 ET | 32125 | 4.3315 |
| 11:02 ET | 5230 | 4.365 |
| 11:03 ET | 9011 | 4.38 |
| 11:05 ET | 29402 | 4.36 |
| 11:07 ET | 2470 | 4.37 |
| 11:09 ET | 8809 | 4.375 |
| 11:12 ET | 28051 | 4.44 |
| 11:14 ET | 2702 | 4.46 |
| 11:16 ET | 9324 | 4.46 |
| 11:18 ET | 36899 | 4.445 |
| 11:20 ET | 13796 | 4.485 |
| 11:21 ET | 9542 | 4.475 |
| 11:23 ET | 4952 | 4.47 |
| 11:25 ET | 6808 | 4.45 |
| 11:27 ET | 7403 | 4.46 |
| 11:30 ET | 5600 | 4.465 |
| 11:32 ET | 15895 | 4.39 |
| 11:34 ET | 3650 | 4.405 |
| 11:36 ET | 13272 | 4.41 |
| 11:38 ET | 1800 | 4.41 |
| 11:39 ET | 2199 | 4.4 |
| 11:41 ET | 3958 | 4.4 |
| 11:43 ET | 1200 | 4.41 |
| 11:45 ET | 11535 | 4.4199 |
| 11:48 ET | 17327 | 4.39 |
| 11:50 ET | 4831 | 4.43 |
| 11:52 ET | 2276 | 4.4484 |
| 11:54 ET | 20562 | 4.39 |
| 11:56 ET | 8260 | 4.38 |
| 11:57 ET | 1258 | 4.365 |
| 11:59 ET | 3505 | 4.37 |
| 12:01 ET | 15601 | 4.325 |
| 12:03 ET | 7133 | 4.34 |
| 12:06 ET | 1165 | 4.36 |
| 12:08 ET | 5071 | 4.325 |
| 12:10 ET | 1291 | 4.33 |
| 12:12 ET | 1770 | 4.315 |
| 12:14 ET | 3708 | 4.29 |
| 12:15 ET | 4640 | 4.295 |
| 12:17 ET | 200 | 4.3 |
| 12:19 ET | 4554 | 4.295 |
| 12:21 ET | 3016 | 4.285 |
| 12:24 ET | 14134 | 4.315 |
| 12:26 ET | 2179 | 4.325 |
| 12:28 ET | 20288 | 4.295 |
| 12:30 ET | 9514 | 4.32 |
| 12:32 ET | 17103 | 4.305 |
| 12:33 ET | 1000 | 4.315 |
| 12:35 ET | 7245 | 4.315 |
| 12:37 ET | 13108 | 4.31 |
| 12:39 ET | 2631 | 4.31 |
| 12:42 ET | 6444 | 4.305 |
| 12:44 ET | 500 | 4.31 |
| 12:46 ET | 11055 | 4.315 |
| 12:48 ET | 3340 | 4.315 |
| 12:50 ET | 15051 | 4.35 |
| 12:51 ET | 20530 | 4.365 |
| 12:53 ET | 8825 | 4.385 |
| 12:55 ET | 18256 | 4.41 |
| 12:57 ET | 20978 | 4.4 |
| 01:00 ET | 125808 | 4.35 |
Nov 27, 2024
Perspective Therapeutics to Participate in Upcoming Investor Conferences in December, from 7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 25, 2024
DJ Perspective Therapeutics Is Maintained at Outperform by RBC Capital, from 10:55AM ET on Monday Nov 25, 2024 by Dow Jones
10:55AM ET on Monday Nov 25, 2024 by Dow JonesDJ Perspective Therapeutics Cut to Neutral From Buy by B of A Securities, from 8:15AM ET on Monday Nov 25, 2024 by Dow Jones
8:15AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 22, 2024
DJ Perspective Therapeutics Is Maintained at Outperform by Oppenheimer, from 9:32AM ET on Friday Nov 22, 2024 by Dow Jones
9:32AM ET on Friday Nov 22, 2024 by Dow Jones
Nov 21, 2024
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-
-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, from 7:15AM ET on Thursday Nov 21, 2024 by Dow Jones 7:15AM ET on Thursday Nov 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Perspective Therapeutics Inc | 277.8M | -3.5x | --- |
Atea Pharmaceuticals Inc | 278.7M | -1.7x | --- |
Nautilus Biotechnology Inc | 281.3M | -4.0x | --- |
Abeona Therapeutics Inc | 278.6M | -2.8x | --- |
aTyr Pharma Inc | 288.8M | -3.8x | --- |
ATAI Life Sciences NV | 290.3M | -2.2x | --- |
Company Information
Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. It is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. It has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Contact Information
- Headquarters
- 2401 Elliott Avenue, Suite 320SEATTLE, WA, United States 98121
- Phone
- 206-676-0900
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Lori Woods
- Chief Executive Officer, Director
- Johan Spoor
- Principal Financial Officer, Principal Accounting Officer
- Jonathan Hunt
- Chief Medical Officer
- Markus Puhlmann
- Independent Director
- Heidi Henson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $277.8M |
|---|---|
Revenue (TTM) | $-3.7M |
Shares Outstanding | 67.4M |
Perspective Therapeutics Inc does not pay a dividend. | |
Beta | 1.14 |
EPS | $-1.24 |
Book Value | $2.67 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
